Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cells

Abstract excerpt

Patients with poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) face a much poorer prognosis than those with differentiated thyroid cancers. Around 25% of PDTCs and 35% of ATCs carry the BRAF V600E mutation, which constitutively activates the MAPK pathway, a key driver of cell growth. Although combining BRAF and MEK inhibitors can shrink tumors, resistance often develops. The exact...

Topics

Open a Topic to create a Post that cites this publication.

• Cell Growth Processes
• Indoles
• Mass Spectrometry
• Mice, SCID
• Mitogen-Activated Protein Kinase 1
• Mitogen-Activated Protein Kinase 3
• Sulfonamides
• Xenograft Model Antitumor Assays

Identifiers and source

Literature Corpus work

0d787281-bc65-5600-8234-b1c01f04c4e2

DOI

10.1101/2025.02.17.637322